by ElasmoAdm1n | Jan 15, 2026 | News, Team
Dr Suhail Nurbhai is a highly accomplished physician-scientist, Dr Nurbhai brings deep expertise in advancing therapeutics from preclinical development through regulatory approval and into the clinic. His leadership will be instrumental as Elasmogen progresses its...
by ElasmoAdm1n | Jan 6, 2026 | News
On the 1st of December 2025, Dr Obinna Ubah was awarded a £715,000 #UKRI Future Leaders Fellowship renewal. This milestone also marks the successful completion of his initial four-year UKRI FLF, which provided ~£2 million in total funding. This funding has...
by ElasmoAdm1n | Sep 10, 2025 | News
Euan Murray (Senior Scientist) will present the latest update on Elasmogen’s super-potent soloMER drug conjugate targeting the TNF-α and JAK pathways, advancing new possibilities for the treatment of autoimmune and inflammatory diseases at ELRIG, The Drug Discovery...
by ElasmoAdm1n | May 14, 2025 | News
Euan Murray (Senior Scientist) will attend Antibody Engineering & Therapeutics in Basel, June 10-12th 2025, and present a talk titled First-in-class Site-directed Targeted soloMER Drug Conjugate for Autoimmune Inflammation. He will describe the synthesis and...
by ElasmoAdm1n | May 5, 2025 | News
Stella Priyanka (Senior Scientist) will be presenting the latest data on our first-in-class soloMER drug conjugate, ELN28, at PEGS Boston Summit, May 2025. Her poster, “Characterization of a Bi-Functional soloMER® Drug Conjugate (SDC) Targeting TNFα and JAK...
by ElasmoAdm1n | Mar 5, 2025 | News
Dr Obinna C Ubah ((Principal Scientist and Future Leaders Fellow(UKRI)) and Dr Euan Murray (Senior Scientist) will be presenting the latest data on our first-in-class soloMER drug conjugate, ELN28. Obinna’s talk, “First-in-class Site-directed targeted...
